TDC
HQL

Thompson Davis & Co’s abrdn Life Sciences Investors HQL Stock Holding History

Thompson Davis & Co’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-509
Closed -$11K – 798
2014
Q1 		$11K Buy
+509
New +$11.3K 0.02% 472

Other funds holding HQL

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return

Thompson Davis & Co's HQL Position: Q2 2014 in Review

Thompson Davis & Co sold out of abrdn Life Sciences Investors (HQL) in Q2 2014, closing a stake of 509 shares — an estimated $11K sold.

Thompson Davis & Co first reported a position in HQL in Q1 2014 and held it in 1 quarter. The position peaked at $11K in Q1 2014. 54 funds tracked by Wall St. Rank hold HQL as of Q2 2014.

  • Thompson Davis & Co reported no remaining abrdn Life Sciences Investors position as of Q2 2014 after selling out during the quarter.
  • Thompson Davis & Co sold 509 abrdn Life Sciences Investors shares in Q2 2014, an estimated $11K.
  • Thompson Davis & Co first reported a position in abrdn Life Sciences Investors in Q1 2014 and held it in 1 quarter.
  • Thompson Davis & Co's abrdn Life Sciences Investors position peaked at $11K in Q1 2014.
  • 54 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2014.

Based on Thompson Davis & Co's 13F filing for Q2 2014, filed 12 Aug 2014.